Arun P Wiita
Overview
Explore the profile of Arun P Wiita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2088
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwok D, Stevers N, Etxeberria I, Nejo T, Colton Cove M, Chen L, et al.
Nature
. 2025 Feb;
639(8054):463-473.
PMID: 39972144
T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system's recognition of cancer-specific antigens. However, their efficacy is limited in tumours with few somatic mutations and substantial...
2.
Tuomivaara S, Teo C, Jan Y, Wiita A, Jan L
Commun Biol
. 2024 Aug;
7(1):1060.
PMID: 39210032
To facilitate our understanding of proteome dynamics during signaling events, robust workflows affording fast time resolution without confounding factors are essential. We present Surface-exposed protein Labeling using PeroxidaSe, HO, and...
3.
Leng K, Cadwell C, Devine W, Tihan T, Qi Z, Singhal N, et al.
Neurol Genet
. 2024 Apr;
10(2):e200142.
PMID: 38586598
Objectives: Mosaic gain of chromosome 1q (chr1q) has been associated with malformation of cortical development (MCD) and epilepsy. Hyaline protoplasmic astrocytopathy (HPA) is a rare neuropathologic finding seen in cases...
4.
Nejo T, Wang L, Leung K, Wang A, Lakshmanachetty S, Gallus M, et al.
Sci Rep
. 2024 Mar;
14(1):6362.
PMID: 38493204
Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter- and intra-tumoral heterogeneity of antigen landscape hampers therapeutic development. Therefore, it is critical to consider alternative...
5.
Nix M, Wiita A
Cytotherapy
. 2024 Mar;
26(7):729-738.
PMID: 38466264
Background Aims: Chimeric antigen receptor T (CAR-T) cells are a remarkably efficacious, highly promising and rapidly evolving strategy in the field of immuno-oncology. The precision of these targeted cellular therapies...
6.
Kasap C, Izgutdina A, Patino-Escobar B, Kang A, Chilakapati N, Akagi N, et al.
bioRxiv
. 2024 Mar;
PMID: 38463958
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify...
7.
Shin D, Kim C, Ross J, Hennick K, Wu S, Paranjape N, et al.
Cell Stem Cell
. 2024 Feb;
31(3):421-432.e8.
PMID: 38382530
Thalamic dysfunction has been implicated in multiple psychiatric disorders. We sought to study the mechanisms by which abnormalities emerge in the context of the 22q11.2 microdeletion, which confers significant genetic...
8.
Wadhwa A, Wang S, Patino-Escobar B, Bidkar A, Bobba K, Chan E, et al.
Clin Cancer Res
. 2023 Dec;
30(5):1009-1021.
PMID: 38109209
Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as an overexpressed therapeutic target in multiple...
9.
Temple W, Nix M, Naik A, Izgutdina A, Huang B, Wicaksono G, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 38007238
Background: Approximately 50% of patients who receive anti-CD19 CAR-T cells relapse, and new immunotherapeutic targets are urgently needed. We recently described CD72 as a promising target in B-cell malignancies and...
10.
Nejo T, Wang L, Leung K, Wang A, Lakshmanachetty S, Gallus M, et al.
bioRxiv
. 2023 Nov;
PMID: 37961484
Background: Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter-and intra-tumoral heterogeneity of antigen landscape hampers therapeutic development. Therefore, it is critical to consider alternative...